Last updated on December 2018

Safety Dose Finding Study of ADVM-043 Gene Therapy to Treat Alpha-1 Antitrypsin (A1AT) Deficiency

Brief description of study

The ADVANCE study is being conducted by Adverum Biotechnologies, Inc. as an open-label, multicenter, dose-escalation study in order to assess the safety and protein expression of ADVM-043 following a single intravenous or intrapleural administration.

Detailed Study Description

Alpha-1 Antitrypsin (A1AT) is a major inhibitor of serine proteases and plays an important role in the lung as an inhibitor of neutrophil elastase. A1AT deficiency is associated with decreases in plasma A1AT levels and is associated with an increased risk for developing asthma, emphysema/COPD, and bronchiectasis. Much of the lung damage is thought to be caused by proteolytic damage from neutrophil elastase and other proteases.

ADVM-043 is an investigational gene therapy product (serotype AAVrh.10 vector) expressing human A1AT that is intended to deliver a functional gene to the liver of patients with A1AT deficiency. Study ADVM-043-01 will study up to 4 dose levels in up to 20 patients and assess the hypothesis that a single administration of an AAV vector expressing the human M-type A1AT (i.e., ADVM-043) to patients with A1AT deficiency is safe and results in persistent therapeutic levels of A1AT in blood and alveolar epithelial lining fluid. The primary endpoint is safety, and changes in plasma A1AT levels at multiple time points up to 52 weeks after dosing. A prophylactic tapering corticosteroid regimen will be used to protect against potential vector induced transaminitis. Subjects will be followed for up to 52 weeks after dosing. After completion of this study, subjects will be asked to enroll in a Long Term Follow Up study.

Clinical Study Identifier: NCT02168686

Contact Investigators or Research Sites near you

Start Over

Igor Barjakatarevic, MD

Ronald Reagan UCLA Medical Center
Santa Monica, CA United States

Mark Brantly, MD

University of Florida
Gainesville, FL United States

Kyle Hogarth, MD

University of Chicago Medical Center
Chicago, IL United States

Friedrich Kueppers, MD

Temple University Hospital
Philadelphia, PA United States

Charlton Strange, MD

Medical University of South Carolina
Charleston, SC United States